Genomics Market Report

Global Genomics Market Size

The global genomics market size was valued at USD 24.01 billion in 2025 and is anticipated to reach USD 26.39 billion in 2026 from USD 56.16 billion by 2034, growing at a CAGR of 9.9% during the forecast period from 2026 to 2034.

Genomics is are technology and services dedicated to decoding, analyzing, and interpreting the genome the complete set of DNA within an organism. It integrates next-generation sequencing (NGS), bioinformatics, gene editing, and molecular diagnostics to enable precision in understanding genetic variation and its implications on health, disease, and biological function. As per the National Human Genome Research Institute, the cost of sequencing a human genome has plummeted from approximately $100 million in 2001 to under $600 in 2023, catalyzing widespread adoption across research and clinical domains. The expansion of genomic databases is equally transformative; the European Nucleotide Archive now hosts over 1.8 billion nucleotide sequences by reflecting an exponential growth in data generation.

MARKET DRIVERS

Rising Prevalence of Genetic and Chronic Diseases

The escalating global burden of genetically influenced disorders is accelerating the growth of the Genomics Market. According to the World Health Organization, noncommunicable diseases such as cancer, cardiovascular conditions, and diabetes account for 74% of all deaths worldwide, with genetic predispositions playing a role in their onset. In the United States alone, the Centers for Disease Control and Prevention reports that over 40 million individuals live with a hereditary condition, including BRCA-related cancers and Lynch syndrome. This widespread genetic susceptibility has intensified demand for early detection and risk stratification tools. For instance, the American Cancer Society estimates that 5% to 10% of all cancer cases are directly linked to inherited mutations, fueling clinical interest in germline testing.

Expansion of Precision Medicine Initiatives

Government-backed precision medicine programs are also accelerating the growth of Genomics Market. The UK Biobank, as detailed by the Wellcome Trust, has sequenced the exomes of 500,000 participants by creating one of the most comprehensive genomic datasets globally to study gene-environment interactions. Similarly, the U.S. All of Us Research Program, managed by the National Institutes of Health, aims to collect genetic and health data from at least one million individuals, with over 675,000 participants enrolled by 2024. These initiatives are generating vast, diverse genomic repositories that enable researchers to identify population-specific variants and therapeutic targets. The integration of genomic data with electronic health records enhances clinical decision-making by allowing for tailored treatments based on individual genetic profiles. As per the Personalized Medicine Coalition, over 40% of newly approved drugs in 2023 were designated as personalized medicines, reflecting a systemic shift toward genomics-driven therapeutics.

MARKET RESTRAINTS

Stringent Regulatory and Ethical Frameworks

The complex regulatory landscapes and ethical concerns surrounding genetic data usage is significantly restraining the growth of the Genomics Market. The General Data Protection Regulation (GDPR) in the European Union imposes strict limitations on the processing of genetic information, requiring explicit consent and limiting data sharing even for research purposes. As reported by the Global Alliance for Genomics and Health, over 60% of European research institutions face delays in multi-country genomic studies due to compliance hurdles. Additionally, the U.S. Genetic Information Nondiscrimination Act, while protective, does not cover life insurance or long-term care, creating apprehension among patients. These legal and societal barriers impede data aggregation and cross-border collaboration, which is slowing the translation of genomic research into clinical applications.

High Infrastructure and Operational Costs

The end-to-end implementation of genomic workflows demands substantial investment in infrastructure and skilled personnel, which is hindering the growth of Genomics Market. As per the Broad Institute of MIT and Harvard, maintaining a high-throughput sequencing facility incurs annual operational costs exceeding $2 million, including equipment maintenance, reagents, and computational storage. Bioinformatics analysis alone accounts for up to 60% of total project expenses in large-scale genomics initiatives, as per Nature Biotechnology. Many low- and middle-income countries lack the computational resources to process terabytes of genomic data generated daily. UNESCO reports that only 18% of African nations possess national bioinformatics capacity, severely limiting their participation in global genomic research. Furthermore, the shortage of trained genomic scientists will also to hamper the growth. According to the Human Genome Organisation, there is fewer than one certified clinical genomicist per million population in over 70 countries.

MARKET OPPORTUNITIES

Integration of Artificial Intelligence in Genomic Interpretation

Artificial intelligence is revolutionizing genomic data analysis by enhancing the speed and accuracy of variant interpretation is to showup new opportunities for the growth of the Genomics Market. DeepMind’s AlphaFold, as published in Nature, has predicted the 3D structures of over 200 million proteins, including those linked to genetic disorders, enabling researchers to infer functional impacts of mutations with unprecedented precision. AI-driven platforms such as Fabric Genomics reduce diagnostic odysseys for rare diseases by automating the prioritization of pathogenic variants, cutting analysis time from weeks to hours. As per a 2023 study in Cell, machine learning models improved the detection of non-coding regulatory variants by 40% compared to traditional methods. The integration of AI with cloud-based genomic platforms allows scalable deployment across healthcare systems.

Growth of Population Genomics in Emerging Economies

The national genomic programs in developing regions are unlocking vast, underrepresented genetic diversity, which contributes to leveraging the growth of the Genomics Market. Saudi Arabia’s Vision 2030 includes the Saudi Human Genome Program, which has sequenced over 200,000 genomes to identify region-specific mutations linked to inherited diseases, as reported by King Abdulaziz City for Science and Technology. Similarly, India’s GenomeIndia initiative, led by the Department of Biotechnology, aims to sequence 10,000 genomes from diverse ethnic groups to build a reference database for the subcontinent. These efforts address the historical underrepresentation of non-European populations in genomic databases. Currently, over 78% of participants in genome-wide association studies are of European descent, according to the National Human Genome Research Institute.

MARKET CHALLENGES

Data Privacy and Security Vulnerabilities

The proliferation of genomic data intensifies risks related to privacy breaches and unauthorized access is a great challenge for the growth of the Genomics Market. A 2023 analysis by the University of California, Berkeley revealed that over 12 million genetic records were exposed in cyberattacks targeting direct-to-consumer genetic testing firms between 2019 and 2022. Unlike conventional data, genomic information is inherently identifiable and immutable, making it a high-value target for malicious actors. The Electronic Frontier Foundation warns that anonymized genomic datasets can be re-identified with as few as 31 unique single-nucleotide polymorphisms.

Inadequate Standardization in Genomic Testing

The absence of universal standards in genomic assay validation and reporting compromises result reliability and clinical utility is also impedes the growth of the Genomics Market. As per the College of American Pathologists, fewer than 45% of clinical laboratories performing hereditary cancer testing use harmonized variant classification guidelines, leading to inconsistent interpretations of the same genetic variant. The Global Variome Shared LOVD database indicates that over 300,000 variants of uncertain significance (VUS) remain unresolved due to fragmented data sharing and divergent analytical pipelines. In cardiology, a 2022 study in Circulation: Genomic and Precision Medicine found that 22% of patients received conflicting results when the same sample was analyzed by different accredited labs. This lack of interoperability hampers clinical adoption and raises medico-legal risks.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Insights

The consumables segment dominated the global genomics market by accounting for 48.3% of the share in 2025 with inherently recurring nature of consumable usage across genomic workflows. Unlike capital-intensive instruments that are purchased infrequently, consumables such as reagents, primers, nucleotides, and sample preparation kits are required for every sequencing or amplification run. As per the Association of Clinical Genomic Scientists, an average next-generation sequencing (NGS) laboratory consumes over $120,000 worth of reagents annually for a single high-throughput platform. The expansion of high-volume testing in oncology and population genomics further amplifies demand. The UK National Genomic Research Library processes more than 100,000 samples per year, necessitating continuous procurement of sequencing kits and extraction reagents.

The services segment is projected to grow at a CAGR of 16.3% from 2026 to 2034 owing to the rising outsourcing of genomic data analysis and interpretation, particularly in clinical diagnostics and pharmaceutical development. As per the European Society of Human Genetics, over 60% of hospitals in Western Europe lack in-house bioinformatics expertise, compelling them to rely on third-party genomic interpretation services. The complexity of variant annotation, especially in rare disease diagnosis, demands specialized algorithms and curated databases, which service providers like Genomics plc and WuXi NextCODE offer as turnkey solutions. The proliferation of cloud-based genomic analysis platforms, such as Google Cloud’s DeepVariant pipeline, enables scalable, cost-effective service delivery, which is accelerating adoption across academic and commercial sectors

By Technology Insights

The sequencing segment was the largest by occupying 52.3% of the Genomics Market share in 2025 with the transformative impact of next-generation sequencing (NGS) in both research and clinical settings. The integration of whole-exome and whole-genome sequencing into newborn screening and cancer profiling has further entrenched its utility. As per the American College of Medical Genetics and Genomics, over 70% of children with undiagnosed neurodevelopmental disorders now undergo exome sequencing as a standard diagnostic step. Additionally, large-scale national programs such as Genomics England’s 100,000 Genomes Project have institutionalized sequencing in public healthcare, which is creating sustained demand for sequencing infrastructure and expertise.

The microarray technology segment is anticipated to grow at a CAGR of 11.8% from 2026 to 2034 with its cost-efficiency and reliability in high-throughput genotyping and copy number variation (CNV) detection. The Affymetrix Axiom Genome-Wide Human Array enables genotyping of over one million SNPs per sample at a cost of under $100, as reported by Thermo Fisher Scientific. In prenatal diagnostics, microarrays remain the gold standard for detecting chromosomal imbalances, where the International Society for Prenatal Diagnosis states that 92% of cytogenetic labs in North America use microarrays for products of conception analysis. Moreover, their compatibility with legacy data systems and lower bioinformatics burden make them ideal for resource-constrained settings,by fostering renewed adoption in emerging markets.

REGIONAL ANALYSIS

North America Genomics Market Analysis

North America was the top performer in the global genomics market by holding 41.3% of the total share in 2025 with a robust ecosystem of innovation, regulatory support, and healthcare integration. The United States hosts over 60% of the world’s high-throughput sequencing facilities, as cataloged by the U.S. Department of Energy’s Joint Genome Institute. Federal initiatives like the All of Us Research Program have accelerated genomic data generation, with over 700,000 participants enrolled by mid-2024. The Food and Drug Administration has approved more than 180 companion diagnostics linked to genomic biomarkers, facilitating precision oncology adoption.

Europe Genomics Market Analysis

Europe was positioned second by accounting for 28.3% of the genomics market share in 2025 due to its coordinated national genomics strategies and strong public healthcare integration. The United Kingdom’s National Health Service (NHS) has embedded whole-genome sequencing into routine care through the NHS Genomic Medicine Service, which aims to sequence 500,000 genomes by 2025. France’s Genomic Medicine 2025 plan has established 12 sequencing platforms across the country, which are processing over 230,000 samples annually, as detailed by the French Ministry of Health. Additionally, the presence of leading genomics firms such as Oxford Nanopore Technologies and Qiagen enhances regional innovation. Europe’s emphasis on ethical governance and data privacy under GDPR also sets a benchmark for responsible genomic deployment.

Asia Pacific Genomics Market Analysis

The Asia Pacific genomics market growth expected to have the highest CAGR in the coming years by rapidly ascending as a strategic hub for genomic innovation. The Beijing Genomics Institute (BGI) operates the world’s largest genomics facility, which has sequenced more than 5 million human genomes to date. Japan’s Initiative on Rare and Undiagnosed Diseases (IRUD) has implemented whole-exome sequencing for over 15,000 patients, achieving a diagnostic rate of 35%, as published by the University of Tokyo. India’s GenomeIndia project has sequenced 10,000 diverse genomes to build a reference database, addressing the underrepresentation of South Asian populations.

Latin America Genomics Market Analysis

Latin America genomics market growth is likely to grow steadily in the next coming years. Brazil’s Oswaldo Cruz Foundation (Fiocruz) has launched a national SARS-CoV-2 genomic surveillance network that has sequenced over 120,000 viral genomes since 2020, according to the Pan American Health Organization. Argentina’s National Institute of Genomic Medicine has initiated population screening for hereditary breast and ovarian cancer, targeting 50,000 women annually. However, infrastructure disparities persist; only 12% of Latin American hospitals have access to NGS platforms, as reported by the Latin American Society of Human Genetics.

Middle East & Africa Genomics Market Analysis

The Middle East and Africa genomics market growth is lucratively growing in the next coming years. Saudi Arabia’s Vision 2030 includes a $1.2 billion investment in genomics through the Saudi Human Genome Program, which has already identified over 1,200 novel disease-causing variants, according to King Abdullah International Medical Research Center. The UAE has established the Centre for Arab Genomic Studies, which maintains the largest database of Arab genetic disorders, covering more than 1,600 conditions. As per UNESCO, H3Africa has trained over 1,200 African scientists in genomics and bioinformatics.

COMPETITIVE LANDSCAPE

The genomics market exhibits intense competition characterized by rapid technological advancements, strategic alliances, and a race for innovation leadership. Established players compete not only on instrument performance but also on total cost of ownership, data accuracy, and integration with clinical workflows. The emergence of regional champions, particularly in Asia Pacific, has intensified pressure on Western firms to localize offerings and adapt to diverse regulatory environments. Differentiation is increasingly driven by software capabilities, including AI-powered variant interpretation and cloud-based analytics. Companies are also competing through ecosystem development, offering end-to-end solutions that combine hardware, consumables, and bioinformatics.

KEY MARKET PLAYERS

In this report, companies playing a promising role in the global genomics market include

• Affymetrix, Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• BGI Group (China)
• Thermo Fisher Scientific Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• GE Healthcare (U.S.)
• Illumina, Inc. (U.S.)
• QIAGEN N.V. (Netherlands)
• Roche Diagnostics (Switzerland)
• Life Technologies Corporation (U.S.)
• Cepheid (U.S.)

Top Players in the Genomics Market

Illumina, Inc.

Illumina has been instrumental in advancing next-generation sequencing (NGS) infrastructure across the Asia Pacific region by enabling large-scale genomic research and clinical diagnostics. The company established a regional sequencing center in Singapore in collaboration with A*STAR, enhancing local capacity for precision medicine. In 2023, Illumina launched the TruSight Oncology 500 assay in Japan, supporting comprehensive genomic profiling for cancer patients. The firm also partnered with Australia’s Garvan Institute to integrate its NovaSeq X systems into population genomics initiatives. By investing in localized technical support and training programs, Illumina has strengthened its foothold in emerging markets such as India and South Korea. Its engagement with public health programs and regulatory bodies ensures alignment with regional needs, reinforcing its role as a foundational technology provider.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific has significantly expanded its genomics footprint in Asia Pacific through strategic collaborations and localized product development. In 2022, the company opened a state-of-the-art manufacturing facility in Shanghai dedicated to producing sequencing reagents and molecular diagnostic kits, ensuring supply chain resilience. It introduced the Oncomine Precision Assays in India and South Korea, tailored to detect region-specific cancer mutations. The firm also collaborated with Japan’s National Cancer Center to validate liquid biopsy panels for early tumor detection.

BGI Genomics

BGI Genomics was headquartered in Shenzhen, is a dominant force in the Asia Pacific genomics landscape by driving innovation in reproductive health, oncology, and agricultural genomics. The company operates one of the world’s largest high-throughput sequencing centers and has contributed to national projects such as China’s Precision Medicine Initiative. In 2023, BGI launched the CoolMPS-based DNBSEQ-T7 system in Southeast Asia, offering cost-effective, high-speed sequencing. It partnered with the Thai Red Cross to enhance neonatal screening using whole-exome sequencing. BGI also supplied genomic surveillance support during regional disease outbreaks, including dengue and mpox. Its commitment to affordable, scalable solutions has positioned it as a key enabler of genomic equity in developing economies.

Top Strategies Used by the Key Market Participants

Key players in the genomics market primarily deploy strategies such as technological innovation, strategic partnerships, geographic expansion, mergers and acquisitions, and vertical integration to consolidate their positions. Companies are investing heavily in R&D to launch high-throughput, cost-efficient sequencing platforms and automated sample preparation systems. Collaborations with academic institutions and government agencies facilitate regulatory approvals and large-scale implementation. Geographic expansion into emerging markets is achieved through localized manufacturing and distribution networks. Mergers and acquisitions enable access to novel technologies and complementary service portfolios. Vertical integration allows firms to control the entire genomics workflow, from instruments to data analysis. Additionally, cloud-based bioinformatics platforms are being developed to enhance user accessibility and real-time data interpretation by strengthening customer retention and service scalability.

RECENT HAPPENINGS IN THIS MARKET

• In January 2022, Illumina launched the NovaSeq X series at the J.P. Morgan Healthcare Conference, introducing a next-generation sequencing platform capable of sequencing 20,000 human genomes annually with 40% lower cost per gigabase by enhancing scalability for large population studies.
• In June 2022, Thermo Fisher Scientific acquired PPD, Inc. for $17.4 billion, integrating clinical trial services with genomic testing to offer end-to-end solutions for pharmaceutical developers conducting biomarker-driven trials.
• In September 2022, BGI Genomics inaugurated a new high-throughput sequencing laboratory in Dubai Science Park, which is expanding its Middle East footprint and enabling localized genomic testing for hereditary diseases and oncology across GCC nations.
• In March 2023, Pacific Biosciences of California launched the Revio system, a high-throughput long-read sequencer that delivers 15,000 human genomes per year by targeting comprehensive variant detection in complex genomic regions.
• In November 2023, Oxford Nanopore Technologies partnered with India’s Council of Scientific and Industrial Research to deploy MinION sequencing devices for real-time pathogen surveillance across 50 research institutes in India.

MARKET SEGMENTATION

This research report segmented and sub-segmented the global genomics market based on the product, application, technology, process, end-user, and region.

By Product

• Instruments/systems
• Consumables
• Services

By Technology

• Sequencing
• Microarray Technology
• PCR
• Nucleic Acid Extraction

By Process

• Library Preparation
• Sequencing
• Imaging
• Data Analysis

By Application

• Diagnostics
• Drug Discovery and Development
• Personalized Medicine
• Agriculture & Animal Research

By End User

• Research Centres
• Hospitals and Clinics
• Pharmaceutical Companies

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa